Jung Won Shin
Jung Won is a reporter based in Seoul covering South Korea, most recently working for PharmAsia News. Her work covers corporate activities in the South Korean pharma/biotech sector as well as government policy and regulatory news. In her role, Jung Won focuses on R&D strategies, clinical development, licensing deals and other major corporate deals and activities in the country's pharma/biotech sector as well as major government measures or regulatory activities in the sector.
Prior to joining Informa, Jung Won worked for Dow Jones Newswires in Seoul, covering stories in various industries and government. Outside of work, she likes to travel and spend time with her family and friends.
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Jung Won Shin
Following its approval in Japan earlier this year, LG Chem's etanercept biosimilar Eucept has gained the green light in South Korea, where it is set to compete directly with Samsung Bioepis's biosimilar this year.
South Korea continues efforts to root out illegal rebate payments for drugs and to step up the pharma industry's ethics and social responsibility by revising relevant rules, but in a way that doesn't harm patients' health.
South Korean companies are seeking diverse ways to enter global drug markets, and SK Biopharmaceuticals is leading the way by establishing physical R&D and commercial operations in the US to progress its CNS drug pipeline. Executives of SK Life Science, the US subsidiary of SK Biopharmaceuticals, talk to Scrip about why they are committed to developing drugs in the US and what advantages and challenges they have by establishing a footprint in this key market.
GC Pharma/Biocon are set to adopt a low price strategy for their biosimilar insulin glargine, which has just received regulatory approval in South Korea, to better compete with rival products.
Celgene will pursue "high-impact" indications using Vividion's proteomics technology, while Magenta will use Heidelberg's technology to try to optimize bone marrow transplants.
South Korean pharma firms are still heavily dependent on generics for revenues, but approvals for required bioequivalence tests continue to drop, indicating that more developers are opting for joint studies and co-development. By therapeutic area, chronic disease drugs led generic development in the country in 2017 amid an aging population and increasingly Westernized eating habits.